Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 2/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14049048 | 0.92 | IKBKB (0.40) | OPRD1OPRM1 | |
| SCHEMBL2877042 | 0.87 | NR1I2 (0.41) | CHEK1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Hydrochloric Acid SCHEMBL2878280 | 0.86 | NR1I2 (0.41) | CHEK1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL27633503 | 0.84 | CHEK1 (0.37) | CHEK1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL14048987 | 0.83 | OPRD1 (0.42) | CHEK1OPRD1OPRM1 | |
| SCHEMBL14136979 | 0.81 | KDM4E (0.48) | OPRD1OPRM1 | |
| SCHEMBL14049041 | 0.79 | KDM4E (0.40) | — | |
| SCHEMBL14031010 | 0.79 | NR1I2 (0.40) | CHEK1 | |
| SCHEMBL2876967 | 0.78 | KDM4E (0.46) | CHEK1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL2876357 | 0.77 | CYP2E1 (0.42) | CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269481-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2008-10-30 | — | — | US | disclosed |
| US-7402608-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2008-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269481-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | ZC3HAV1, ZYX, ZFX | CHEK1 4773/4885OPRD1 4221/4885CHRNB2 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.